Ludwig Enterprises Inc. Announces New Leadership Appointment of Charles T. Todd, Jr.

Rhea-AI Summary

Ludwig Enterprises (LUDG) has appointed Charles T. Todd, Jr. as CEO and Chairman of the Board to lead the company's transformation from a research and diagnostic development business to a healthcare solutions provider. Todd brings over 40 years of experience in the Clinical Laboratory Industry, notably founding the first cancer specialty laboratory in the US.

Todd's previous achievements include his 20-year tenure at BioReference Laboratories, where he served as Executive Vice President and led the company's growth to become the third-largest clinical laboratory in the United States. BioReference was ultimately sold to OPKO Health for $1.2 billion in 2015.

The company is developing a patent-pending cancer screening technology utilizing 48 mRNA markers, nanoscale detection, and AI to provide non-invasive early detection through cheek swab testing, particularly focusing on breast cancer screening.

Positive

• Appointment of highly experienced executive with proven track record in clinical laboratory industry
• New CEO's previous success in scaling BioReference to third-largest clinical lab in US
• Development of innovative non-invasive cancer screening technology with AI integration
• Strategic shift towards healthcare solutions provider indicates commercialization focus

Negative

• Company undergoing significant business model transition, which carries execution risks
• Cancer screening technology still in development phase, not yet commercialized

Charles T. Todd, Jr. named CEO and Chair of the Board

MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / Ludwig Enterprises, Inc. (the "Company"), has appointed Charles T. Todd, Jr. as Chief Executive Officer and Chairman of the Board of Directors, to oversee the Company's transition from an innovative research and diagnostic development business to a healthcare solutions provider. Mr. Todd has over 40 years of experience in the Clinical Laboratory Industry in addition to overseeing the growth and development of other innovative healthcare companies.

Mr. Todd founded the first cancer specialty laboratory in the United States which was subsequently acquired by BioReference Laboratories, Inc. ("BioReference") where he was ultimately promoted to Executive Vice President. Mr. Todd was responsible for all sales, marketing, laboratory acquisitions and payor contracts. During his 20 year tenure with BioReference, Mr. Todd led their growth from a northeast regional laboratory to the third largest clinical laboratory in the United States. BioReference was sold to OPKO Health, Inc. for $1.2 Billion Dollars in 2015. Mr. Todd left BioReference two years after the sale and since leaving Mr. Todd has helped other medical device companies establish new markets and develop operational excellence. As CEO and Chair of the Board of Directors, Mr. Todd brings a unique vision to architect and execute the transition of the company.

The Company is excited to bring him aboard and leverage his vast experience commercializing new products and services in the clinical laboratory and cancer diagnostics industry.

Marvin S. Hausman, MD, Co-Founder and Chief Science Officer of the Company, articulated: "Mr. Todd has exceptional knowledge, insight, and experience in clinical diagnostic laboratory operations. His strategic plans for our growth will be as rewarding to our shareholders as it will be to the patient community as we roll out our cancer diagnostic program, especially our noninvasive cheek cell breast cancer test.

We are transforming the Cancer Screening Market. Our patent-pending technology uses 48 mRNA markers, nanoscale detection, and artificial intelligence (AI) to provide a non-invasive, painless, convenient, and highly accurate multi-cancer early detection screening via a simple Cheek Swab. This innovative approach gives us a strong competitive edge.

Mr. Todd stated: "I am honored and humbled to accept the positions of Chief Executive Officer and Chairman of the Company. There is enormous potential here, and I relish the challenges ahead. I have had a long and successful career, and this opportunity will be the crown jewel of my professional life."

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc. (which is in the process of changing its name to Revealia Diagnostics, Inc.), a biotech and healthcare holding company, is a global - innovator in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to -mitigate chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than 50% of deaths worldwide.

For more information, please visit: http://www.ludwigent.com.

About Revealia Diagnostics™

Revealia™ is a breast cancer screening test that utilizes a proprietary mRNA microarray to establish a personalized inflammatory index that provides a patient with reliable information that can assist in their healthcare medical decisions. - Artificial intelligence (AI) is used to determine a risk score, which is derived from a specific array of inflammatory biomarkers and comparing it to a database of previously analyzed patients.

For more information, please visit: www.revealia.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

FOR FURTHER INFORMATION:

CONTACT:

Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: @LUDG_inc

SOURCE: Ludwig Enterprises, Inc.

View the original press release on ACCESS Newswire

FAQ

What experience does Charles T. Todd Jr. bring to Ludwig Enterprises (LUDG)?

Charles T. Todd Jr. brings 40+ years of Clinical Laboratory Industry experience, founded the first US cancer specialty laboratory, and led BioReference Laboratories to become the third-largest clinical lab in the US as Executive VP.

What is Ludwig Enterprises' (LUDG) main cancer screening technology?

LUDG is developing a non-invasive cancer screening test using 48 mRNA markers, nanoscale detection, and AI, administered through a cheek swab, with focus on breast cancer detection.

How successful was Charles T. Todd Jr.'s previous venture at BioReference Laboratories?

Under Todd's leadership, BioReference grew from a regional laboratory to the third-largest clinical laboratory in the US, leading to its $1.2 billion acquisition by OPKO Health in 2015.

What is Ludwig Enterprises' (LUDG) business transformation strategy?

LUDG is transitioning from a research and diagnostic development business to a healthcare solutions provider, focusing on commercializing their cancer diagnostic program.